<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">camrelizumab based treatment</span> <span style="margin-left: 3em;">camrelizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (3) progression or deaths (PFS) (2) objective responses (ORR) (2) DOR (2) DCR (1) TRAE (any grade) (2) TRAE (grade 3-4) (2) TRAE leading to death (grade 5) (2) TRAE leading to discontinuation (any grade) (2) AE leading to death (grade 5) (2) AE (any grade) (1) TRAE leading to discontinuation (grade 3-4) (1) STRAE (any grade) (1) STRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (2) Diarrhoea TRAE (grade 3-4) (2) Neutropenia TRAE (grade 3-4) (2) Nausea TRAE (grade 3-4) (2) Decreased appetite TRAE (grade 3-4) (2) Colitis TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (1) Pneumonitis TRAE (grade 3-4) (1) Maculopapular rash TRAE (grade 3-4) (1) Asthenia TRAE (grade 3-4) (1) Dyspnoea TRAE (grade 3-4) (1) Thrombocytopenia TRAE (grade 3-4) (1) Vomiting TRAE (grade 3-4) (1) Leucopenia TRAE (grade 3-4) (1) Abdominal pain TRAE (grade 3-4) (1) Adrenal insufficiency TRAE (grade 3-4) (1) Hypersensitivity TRAE (grade 3-4) (1) Pancreatitis TRAE (grade 3-4) (1) Myocarditis TRAE (grade 3-4) (1) Hypertension TRAE (grade 3-4) (1) Reactive cutaneous capillary endothelial proliferation TRAE (grade 3-4) (1) Alopecia TRAE (grade 3-4) (1) Fatigue TRAE (grade 3-4) (1) Peripheral neuropathy TRAE (grade 3-4) (1) Stomatitis TRAE (grade 3-4) (1) Anaemia TRAE (grade 3-4) (1) Rash TRAE (grade 3-4) (1) Arthralgia TRAE (grade 3-4) (1) Peripheral sensory neuropathy TRAE (grade 3-4) (1) Anaemia AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 ATTRACTION-3, 2019 1 KEYNOTE-181, 2020 1 ESCORT, 2020 camrelizumab alone vs. nivolumab alone
0.92 [0.68; 1.25] 0.92 [0.68;1.25]camrelizumab alone vs. nivolumab alone
0.92 [0.68; 1.25] camrelizumab alone vs. pembrolizumab alone
0.80 [0.61; 1.05] 0.80 [0.61;1.05]camrelizumab alone vs. pembrolizumab alone
0.80 [0.61; 1.05] camrelizumab alone vs. Standard of Care (SoC)
camrelizumab alone better
0.71 [0.57; 0.88] 0.71 [0.57;0.88]camrelizumab alone vs. Standard of Care (SoC)
camrelizumab alone better
0.71 [0.57; 0.88] nivolumab alone vs. camrelizumab alone
1.08 [0.80; 1.47] 1.08 [0.80;1.47]nivolumab alone vs. camrelizumab alone
1.08 [0.80; 1.47] nivolumab alone vs. pembrolizumab alone
0.87 [0.66; 1.14] 0.87 [0.66;1.14]nivolumab alone vs. pembrolizumab alone
0.87 [0.66; 1.14] nivolumab alone vs. Standard of Care (SoC)
nivolumab alone better
0.77 [0.62; 0.96] 0.77 [0.62;0.96]nivolumab alone vs. Standard of Care (SoC)
nivolumab alone better
0.77 [0.62; 0.96] pembrolizumab alone vs. camrelizumab alone
1.25 [0.96; 1.64] 1.25 [0.96;1.64]pembrolizumab alone vs. camrelizumab alone
1.25 [0.96; 1.64] pembrolizumab alone vs. nivolumab alone
1.16 [0.88; 1.52] 1.16 [0.88;1.52]pembrolizumab alone vs. nivolumab alone
1.16 [0.88; 1.52] pembrolizumab alone vs. Standard of Care (SoC)
0.89 [0.75; 1.05] 0.89 [0.75;1.05]pembrolizumab alone vs. Standard of Care (SoC)
0.89 [0.75; 1.05] Standard of Care (SoC) vs. camrelizumab alone
camrelizumab alone better
1.41 [1.14; 1.74] 1.41 [1.14;1.74]Standard of Care (SoC) vs. camrelizumab alone
camrelizumab alone better
1.41 [1.14; 1.74] Standard of Care (SoC) vs. nivolumab alone
nivolumab alone better
1.30 [1.04; 1.62] 1.30 [1.04;1.62]Standard of Care (SoC) vs. nivolumab alone
nivolumab alone better
1.30 [1.04; 1.62] Standard of Care (SoC) vs. pembrolizumab alone
1.12 [0.95; 1.33] 1.12 [0.95;1.33]Standard of Care (SoC) vs. pembrolizumab alone
1.12 [0.95; 1.33] Standard of Care (SoC) nivolumab alone pembrolizumab alone camrelizumab alone direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) nivolumab alone pembrolizumab alone camrelizumab alone Standard of Care (SoC) --- 1.30 1.04; 1.621.12 0.95; 1.331.41 1.14; 1.74nivolumab alone 0.77 0.62; 0.96--- 0.87 0.66; 1.141.08 0.80; 1.47pembrolizumab alone 0.89 0.75; 1.051.16 0.88; 1.52--- 1.25 0.96; 1.64camrelizumab alone 0.71 0.57; 0.880.92 0.68; 1.250.80 0.61; 1.05---
pathologies: 148
- treatments: 661
result logic